Beat AML Trial to Expand into MDS Therapy

At the European Hematology Association 2024 Congress, Lore Gruenbaum, PhD, Vice President of the Therapy Acceleration Program at the Leukemia & Lymphoma Society, discusses the Beat AML trial in acute myeloid leukemia and its expansion into myelodysplastic syndromes (MDS) therapy.

Since 2016, the Beat AML trial has provided practice-changing insights such as the ability to incorporate genetic profiling and delay treatment for up to seven days, Dr. Gruenbaum said. The trial also allows investigators to assess the potential for novel agents to benefit patients.

“With Beat AML, we're focusing on frontline therapeutic options,” she continued. “Because it's a master study, it can be used to provide larger analysis that can help understand risk stratification and how patient populations are changing.”

Dr. Gruenbaum also discussed the expansion of Beat AML to include patients with high-risk MDS.

 “What we're seeing is the reclassification of high-risk MDS, with some patients now falling under AML,” she said. “For a while, we thought about including high-risk MDS. This is something that we see coming very soon.”